Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Xtant Medical (NYSE:XTNT) reported strong Q4 and full-year 2024 results, with annual revenue growing 28% to $117.3 million. Q4 revenue increased 12% year-over-year to $31.5 million, driven by biologics product growth.
The company's gross margin decreased to 50.8% in Q4 2024 from 61.0% in Q4 2023, while full-year margin dropped to 58.2% from 60.8%. Net loss for 2024 was $16.4 million compared to net income of $660,000 in 2023.
Key developments include a new manufacturing agreement worth $1.5 million upfront, $5 million in cost reductions, and projected 2025 revenue guidance of $126-130 million. Management expects to generate free cash flow in H2 2025 without requiring additional external capital.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has scheduled its Fourth Quarter and Year End 2024 financial results announcement for March 6, 2025, after market close.
The company will host a conference call at 4:30 PM ET on the same day, featuring President and CEO Sean Browne and CFO Scott Neils. Investors can access the call via domestic (888-506-0062) or international (973-528-0011) dial-in numbers using passcode 907938. A webcast will be available, with a replay accessible later on the company's website.
Xtant Medical reported Q3 2024 financial results with revenue of $27.9 million, up 12% year-over-year, and year-to-date revenue of $85.8 million, up 36%. The company posted a net loss of $5.0 million compared to net income of $9.2 million in Q3 2023. Gross margin decreased to 58.4% from 61.3%. Notable developments include launching OsteoVive+ and Cortera Posterior Fixation System, signing a license agreement worth minimum $5.25 million, and completing a $5.0 million private placement. The company reaffirmed its full-year 2024 revenue guidance of $116-120 million, representing 27-31% growth.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, at the Sheraton NY Times Square Hotel in New York City. CEO Sean Browne and CFO Scott Neils will represent the company in one-on-one meetings during the conference.
Xtant Medical Holdings (NYSE American: XTNT) announced it will release its third quarter 2024 financial results on November 12, 2024, after market close. The company will host a conference call at 4:30 PM ET the same day, featuring President and CEO Sean Browne and CFO Scott Neils. The call will be accessible via phone and webcast, with a replay available on the company's website afterward.
Xtant Medical Holdings, Inc. (NYSE American:XTNT) has launched the Cortera Posterior Fixation System, a comprehensive solution for thoracolumbar fixation surgeries. Now available in the United States, Cortera aims to enhance surgical efficiency and provide versatile solutions for complex spine procedures. Key features include:
- Dual Lead and Dual-to-Quad Lead screw thread options
- 5.5/6.0mm Ti/CoCr Rod System
- Helical Flange design
- Universal S27 Hexalobe Drive
The system is designed to simplify both straightforward and complex posterior fixation procedures, addressing spinal deformities, fractures, and degenerative conditions. Xtant Medical will showcase Cortera at the NASS 2024 Annual Meeting in Chicago, IL, from September 25-28, 2024.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has launched OsteoVive Plus, a new moldable, viable bone matrix for various grafting procedures. This product expands Xtant's portfolio and is now available to their nationwide distribution network. OsteoVive Plus features Advanced Purloc™ Fiber Technology, offering a high concentration of elongated cortical fibers for optimal surgical placement.
The launch aligns with Xtant's strategy to drive margin improvement and generate positive operating cash flow. Manufactured at their Belgrade facility, OsteoVive Plus reinforces Xtant's position as an innovative medical technology company. The product will be showcased at the North American Spine Society (NASS) 2024 annual meeting from September 25-28 in Chicago.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has announced a $5.0 million private placement of common stock. The company will issue 7,812,500 shares at $0.64 per share to an existing institutional investor. The proceeds will be used for working capital and general corporate purposes.
The private placement is expected to close around August 9, 2024, subject to customary conditions. Craig-Hallum Capital Group is acting as the sole placement agent. The transaction is being conducted under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. Xtant Medical has agreed to file a registration statement with the SEC for the resale of the issued shares.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal disorders, has announced its upcoming second quarter 2024 financial results release and earnings conference call. The company will disclose its financial results for the quarter ended June 30, 2024, after market close on Thursday, August 8, 2024.
A conference call to discuss the results is scheduled for Friday, August 9, 2024, at 9:00 AM ET. The call will be hosted by Sean Browne, President and CEO, and Scott Neils, CFO. Investors can join via phone or webcast, with replay available on the company's website post-call.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong financial results for Q2 2024, with revenue increasing 48% to $29.9 million. The company's gross margin improved by 50 basis points to 62.1%. Despite a net loss of $3.9 million, Xtant achieved positive Adjusted EBITDA of $0.5 million.
Key highlights include the launch of two new amniotic membrane allograft products, signing 15 new distributors, and securing 20 IDN contracts. The company also entered a $5.0 million private placement to strengthen its balance sheet.
Xtant reaffirmed its 2024 revenue guidance of $116-$120 million, projecting 27-31% annual growth. The company expects continued momentum with new product launches, increased distributor penetration, and improved margins in the second half of 2024.